Cure8 research brief
This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure clinicians and patients about applicability across populations.
Adults with moderate–severe ulcerative colitis, clinicians treating UC, researchers interested in JAK inhibitors and population-specific pharmacokinetics, and patients considering or on advanced therapies for UC.
The analysis pooled data from the U‑ACHIEVE and U‑ACCOMPLISH induction studies and the U‑ACHIEVE maintenance study. East Asian patients receiving upadacitinib 45 mg for induction and 15 mg or 30 mg for maintenance had greater remission and endoscopic outcome rates than placebo.
Herpes zoster events were observed but described as low in number; overall safety and pharmacokinetic profiles in East Asian patients were reported as consistent with the global population.
The report is an abstract-level post hoc subanalysis of already completed phase 3 randomized trials; it summarizes efficacy, safety, and pharmacokinetic comparisons rather than presenting new randomized data limited to East Asia alone.
If you are considering treatment changes, discuss the full trial publications and product labeling with your clinician — this note is a factual summary, not medical advice.
This is a post hoc subanalysis (abstract-level) of phase 3 randomized trials; subanalyses can be useful but have limitations compared with prespecified primary analyses. The source reports consistency with the global program but does not replace individualized clinical decision-making.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: AbbVie
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
